Short-course of oral miltefosine for treatment of visceral leishmaniasis

Clin Infect Dis. 2000 Oct;31(4):1110-3. doi: 10.1086/318122.

Abstract

A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Antiprotozoal Agents / administration & dosage*
  • Antiprotozoal Agents / adverse effects
  • Diarrhea / chemically induced
  • Drug Administration Schedule
  • Female
  • Humans
  • Leishmaniasis, Visceral / drug therapy*
  • Male
  • Phosphorylcholine / administration & dosage
  • Phosphorylcholine / adverse effects
  • Phosphorylcholine / analogs & derivatives*
  • Vomiting / chemically induced

Substances

  • Antiprotozoal Agents
  • Phosphorylcholine
  • miltefosine